Filter Results
Clinical Studies
Results filtered:Study status:
Open
Contact Us for the Latest Status
Closed for Enrollment
Open
-
A Single-blind Phase II, Multi-center, Randomized Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients with Hepatorenal Syndrome – Acute Kidney Injury
Rochester, Minn.,
Jacksonville, Fla.,
Scottsdale/Phoenix, Ariz.
The purpose of this study is to evaluate the safety and effectiveness of R2R01 combined with terlipressin as compared to terlipressin alone in the treatment of patients with Hepatorenal Syndrome - Acute Kidney Injury (HRS-AKI).
-
Chronic Liver Disease Evolution and Registry for Event and Decompensation (CLEARED) Global Study of Liver Disease Outcomes in Inpatients (CLEARED)
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.
The purpose of this study is to evaluate the outcome of hospitalization related to the presence of cirrhosis. We are participating in optional blood, saliva, urine, ascitic fluid and stool collection.
Contact Us for the Latest Status
Closed for Enrollment
-
A Multi-Center, Randomized, Placebo Controlled, Double-Blind Study to Confirm Efficacy and Safety of Terlipressin in Subjects with Hepatorenal Syndrome Type 1 (The CONFIRM Study)
Jacksonville, Fla.
The purpose of this study is to confirm the effectiveness and safety of intravenous terlipressin in the treatment of adult patients who have hepatorenal syndrome (HRS) type 1.
-
A Phase 2 Randomized, Controlled, Dose-titration, Open-Label Study Evaluating the Safety and Efficacy of BIV201 in Addition to Standard of Care Compared to Standard of Care to Reduce the Recurrence of Ascites and Complications in Patients with Refractory Ascites Secondary to Decompensated Liver Cirrhosis
Rochester, Minn.,
Jacksonville, Fla.
The purpose of this study is to evaluate the clinical effectiveness of BIV201 continuous infusion in addition to SOC compared to SOC alone in adult patients with refractory ascites secondary to decompensated hepatic cirrhosis.
-
An Expanded Access Phase II Study of Sofosbuvir with Ribavirin and with or without Pegylated Interferon for 24 Weeks in Subjects who have Undergone Liver Transplantation and who have Aggressive, Recurrent Hepatitis C Infection
Jacksonville, Fla.
The purpose of this study, is to open expanded access at specific clinical sites at the request of an investigator for the treatment of individual subjects for whom there are no other treatment options. Patients who have an aggressive, recurring hepatitis C infection following liver transplant, will be given sofosbuvir combined with ribavirin, and pegylated interferon may or may not be added at the discretion of the investigator.
-
Chronic Liver Disease Evolution and Registry for Event and Decompensation (CLEARED) Global Study of Liver Disease Outcomes in Inpatients (CLEARED)
Jacksonville, Fla.
The purpose of this study is to evaluate the outcome of hospitalization related to the presence of cirrhosis. We are participating in optional blood, saliva, urine, ascitic fluid and stool collection.
-
Liver Transplant Registry
Jacksonville, Fla.
The purpose of this study is to evaluate genes collected comparing a recipient's serum, a recipient's original liver and the donor liver graft to determine the characteristics of livers that are susceptible versus resistant to recurrent disease, to reduce the likelihood of liver graft failure in the long-term.
-
The HepQuant SHUNT Liver Diagnostic Kit for Likelihood of Large Esophageal Varices: The SHUNT-V Study
Rochester, Minn.,
Jacksonville, Fla.
The purpose of this study is to validate the Disease Severity Index (DSI) from the HepQuant SHUNT Liver Diagnostic Kit (Test) for likelihood of large esophageal varices.
.